The global drug-eluting balloon market is expected to reach US$ 1,870.60 Mn in 2027 from US$ 516.65 Mn in 2018

This article was originally published on this site

New York, Feb 14, 2020 (GLOBE NEWSWIRE via COMTEX) — New York, Feb. 14, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Drug-Eluting Balloon Market to 2027 – Global Analysis and Forecasts by Product Type ; End User, and Geography” – https://www.reportlinker.com/p05862098/?utm_source=GNW
Whereas, the market is expected to have slow growth due to high cost of procedures and products and stringent regulations for approval during the forecast period.

The drug-eluting balloon market comprises various market leaders and emerging players. Medtronic plc, Boston Scientific Corporation, Cook Medical, and Royal Philips (a part of Koninklijke Philips N.V) are among the market leaders, while there are various emerging players operating in the market. These companies are engaged in the constant development of various medical devices. They have developed these products further to ensure their sustenance in the global market. For instance, in November 2019, Medtronic received the US Food and Drug Administration (FDA) approval for its In. Pact AV drug-coated balloon used in the treatment of failing arteriovenous (AV) access in patients suffering from end-stage renal disease (ESRD), undergoing dialysis. Similarly, Royal Philips has launched two new balloons to its Stellarex portfolio of 0.035-inch, low-dose, drug-coated balloons; the additions include 200mm and 150mm Stellarex 0.035-inch low-dose drug-coated balloons. The products have received FDA approval for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries in upper legs.

Such launches of innovative products by market leaders and new players are driving the growth of the drug-eluting balloon market. This is mainly attributed to the fact that these products have expanded treatment options for physicians to treat peripheral artery diseases (PADs), cardiovascular conditions, and renal artery conditions, and so on.

The drug-eluting balloon market is segmented on the basis of product type, and end user.The market based on product type segment is classified as coronary drug eluting balloons, peripheral drug eluting balloons and other product types.

Based on end user the market is segmented as hospitals, cath labs & cardiac centers, and ambulatory surgical centers.
Read the full report: https://www.reportlinker.com/p05862098/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 

(C) Copyright 2020 GlobeNewswire, Inc. All rights reserved.